Ogremorphin
Based on 2 publication(s) in Google Scholar
Ogremorphin (OGM) is a G protein coupled sensor GPR68 inhibitor with anti-inflammatory and anti-tumor activities. Ogremorphin can inhibit the migration of human melanoma cells and induce ferroptosis in glioblastoma cells.
For research use only. We do not sell to patients.
- Purity: 99.13%
- CAS No.: 352563-21-4
- Formula: C21H17N3OS
- Molecular Weight:359.44
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ogremorphin
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
ELISA
-
Cell Imaging/Staining
-
Histological Imaging/Staining
Biological Activity
GPR68[1].
Ogremorphin (1-5 µM) can reduce the release of inflammatory factors induced by lipopolysaccharide or acidosis in human pulmonary artery endothelial cells, and inhibit inflammatory responses[1]. Ogremorphin (5 µM, 5 days) can inhibit the migration of human melanoma WM-115 cells[2]. Ogremorphin (0-100 µM, 72 h) can induce ferroptosis and inhibit tumor cell viability in glioblastoma U87 cells by promoting the expression of iron death related markers and mediators[3]. Ogremorphin (0-100 µM) can reduce the survival rate of patient derived cell lines (PDX and neurospheres), with LC50 value of 0.42-2.7 µM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U87 and U138 cell lines
-
Concentration:0-100 µM
-
Incubation Time:72 h
-
Result:Reduced the vitality of glioblastoma cells.
-
Cell Line:Human pulmonary arterial endothelial cells (HPAECs)
-
Concentration:1-5 µM
-
Incubation Time:
-
Result:Reduced the upregulation of inflammatory cytokine/chemokine genes TNF - α, ICAM-1, VCAM-1, IL-6, IL-8, IL-1 β, and CXCL5.
-
Cell Line:WM115, A2050 and MEWO cell lines
-
Concentration:5 µM
-
Incubation Time:5 days
-
Result:Inhibited migration in WM115, A2050 and MEWO cell lines.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Zebrafish[3].
-
Dosage:10 μM
-
Administration:Added to a 96 well microtiter plate (5 embryos/well) arranged with zebrafish fertilized eggs
-
Result:Induced phenotypes encompassing a wavy notochord, abnormal pigmentation, craniofacial defects, ventral curvature, and a shortened body axis.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 352563-21-4
-
Appearance Solid
-
Molecular Weight 359.44
-
Formula C21H17N3OS
-
Color Yellow to orange
-
SMILES
O=C1NC2=CC=C(CC)C=C2C13SC(C4=C5C=CC=CC5=CC=C4)=NN3
-
Synonyms
OGM; GPR68-IN-1; OGM-8345
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Inflammation
Pharmacological Activation of GPR68 Attenuates Ferroptosis in Spinal Cord Ischemia/Reperfusion Injury Through PI3K/Akt-Mediated Nrf2 Antioxidant Pathway. [Abstract]2025 Jun 18. PMID: 40528120 -
Biology (Basel)
Targeting GPR68 Alleviates Inflammation and Lipid Accumulation in Metabolic Dysfunction-Associated Steatohepatitis. [Abstract]2026 Jan 26;15(3):233. PMID: 41677704
Ogremorphin purchased from MedChemExpress. Usage Cited in: Biology (Basel). 2026 Jan 26;15(3):233. [Abstract]
HepG2 cell viability after Ogremorphin (OGM) (1, 2.5 5, 10 μM) treatment.
Ogremorphin purchased from MedChemExpress. Usage Cited in: Biology (Basel). 2026 Jan 26;15(3):233. [Abstract]
HepG2 cells pretreated with OA/PA were treated with different concentrations of Ogremorphin (OGM) (1, 2.5 μM) or vehicle for 24 h, and IL-6 levels in the cell culture supernatant were measured.
Ogremorphin purchased from MedChemExpress. Usage Cited in: Biology (Basel). 2026 Jan 26;15(3):233. [Abstract]
HepG2 cells were co-treated with OA/PA (2:1, 750 μM) and 2.5 μM Ogremorphin (OGM) (2.5 μM) or vehicle (Veh) at 0, 6, 12, and 24 h. Representative images of Oil Red O staining.
Ogremorphin purchased from MedChemExpress. Usage Cited in: Biology (Basel). 2026 Jan 26;15(3):233. [Abstract]
Representative H&E and Oil Red O staining of mouse liver tissue treated with Ogremorphin (OGM) (30 mg/kg).
Solvent & Solubility
DMSO : 50 mg/mL (139.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (3.48 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7821 mL | 13.9105 mL | 27.8211 mL | 69.5526 mL |
| 5 mM | 0.5564 mL | 2.7821 mL | 5.5642 mL | 13.9105 mL | |
| 10 mM | 0.2782 mL | 1.3911 mL | 2.7821 mL | 6.9553 mL | |
| 15 mM | 0.1855 mL | 0.9274 mL | 1.8547 mL | 4.6368 mL | |
| 20 mM | 0.1391 mL | 0.6955 mL | 1.3911 mL | 3.4776 mL | |
| 25 mM | 0.1113 mL | 0.5564 mL | 1.1128 mL | 2.7821 mL | |
| 30 mM | 0.0927 mL | 0.4637 mL | 0.9274 mL | 2.3184 mL | |
| 40 mM | 0.0696 mL | 0.3478 mL | 0.6955 mL | 1.7388 mL | |
| 50 mM | 0.0556 mL | 0.2782 mL | 0.5564 mL | 1.3911 mL | |
| 60 mM | 0.0464 mL | 0.2318 mL | 0.4637 mL | 1.1592 mL | |
| 80 mM | 0.0348 mL | 0.1739 mL | 0.3478 mL | 0.8694 mL | |
| 100 mM | 0.0278 mL | 0.1391 mL | 0.2782 mL | 0.6955 mL |
Ogremorphin Related Classifications
HY-154954 Related Classifications
Powered by Bioz